FDA says "close but no cigar" as Anavex considers it's options after Excellence data. That good enough? or perhaps FDA recommends Missling consider inappropriate superlatives when claiming "ALL' i when interpreting trial data. or ultimately Anavex seeking partnership as FDA demands further trial.
I guess there is the possibility of "BSIG throws massive $M Club party after Excellence results only to skip out on tab due to lack of resources (dry powder)"